CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Universidade de São Paulo (USP). Faculdade de Ciências Farmacêuticas (FCF) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Rosario Dominguez Crespo Hirata is a pharmacist with MSc and PhD from the University of São Paulo (Brazil), and a postdoctoral degree from the US Food and Drug Administration (USA). She is a retired professor at the School of Pharmaceutical Sciences at the University of Sao Paulo (FCF/USP). Prof. Rosario investigates the molecular basis of metabolic and cardiovascular diseases using genomic, pharmacogenomic and epigenomic approaches. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Pharmacogenomics and epigenomics may help to understand the mechanisms involved in therapeutic response and nephropathy and/or rejection of renal allograft. This project aims to investigate the role of pharmacogenomics and epigenomics factors in response to immunosuppressive drugs used in the therapy of kidney transplant recipients. Patients submitted to kidney transplant who participated…
Cardiovascular disease (CVD) is considered the main cause of mortality worldwide, creating a serious public health problem and a high cost to the health systems. The etiology of CVD is multifactorial and it has several risk factors, such as dyslipidemia among others. Statins, inhibitors of cholesterol synthesis, are the most prescribed medications for dyslipidemia treatment. In different …
Calcineurin inhibitors such as tacrolimus are used in the treatment of renal transplant recipients to prevent acute rejection. Prolonged use of this drug can result in side effects that contribute to decreased survival of the transplanted kidney. In order to avoid this outcome studies suggest the conversion to sirolimus therapy. However, the molecular mechanisms involved in the response t…
(Only some records are available in English at this moment)
Understanding the genetic factors involved in variations in responses to immunosuppressants can improve efficacy and limit toxicity in transplant therapy. This pharmacogenetic study aims to investigate associations between genetic polymorphisms that affect the pharmacokinetics of tacrolimus (TAC), everolimus (EVR), and mycophenolate sodium (MPS) and the clinical outcomes in kidney transpl…
Familial Hypercholesterolemia (FH) is a primary dyslipidemia with frequent monogenic inheritance resulting from functional mutations in the Low Density Lipoprotein Receptor (LDLR), apolipoprotein B (APOB) and Proprotein convertase subtilisin/kexin type 9 (PCSK9) genes, which codify proteins that regulate cholesterol homeostasis. The first-line treatment consists of the use of statins, suc…
What makes organ transplantation and the patient response to drug therapy especially complex is the nature of the drugs that are used, the number of polymorphic factors that play a role in drug responsiveness and the lack of understanding of the acute and chronic processes that jeopardize organ function and survival. Today, a major goal of immunosuppressive therapy is the individualized t…
(Only some records are available in English at this moment)
Familial hypercholesterolemia (FH) is a primary dyslipidemia resulting from functional mutations in cholesterol homeostasis genes. Statins are the first-line treatment, but the response is highly variable among individuals. Pharmacogenetic scores have been developed to predict this variability, but none is specific to the Brazilian FH population. Also, the impact of variants found on prod…
The narrow therapeutic index of the immunosuppressive drugs and the several factors influencing the pharmacological response contribute to make the patient monitoring especially complex in the organ transplantation. That is way, the individualization of treatment is an important tool that can contribute to the reduction of acute rejection events, improve efficacy and decrease the toxic or…
| 25 / 16 | Completed research grants |
| 19 / 9 | Completed scholarships in Brazil |
| 2 / 2 | Completed scholarships abroad |
| 46 / 27 | All research grants and scholarships |
| Associated processes | |